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Bleomycin, an antibiotic agent with antitumour activity, is an important drug in the management of many oncological
malignancies such as lymphoma and germ cell tumours. These tumours are potentially curable and mostly affect young
people. The potential side effects and long-term toxicities should be considered. The major limitation of bleomycin therapy
is pulmonary toxicity and may be life threatening in about 10% of cases. This article reports a case of an ovarian mixed
germ cell tumour, which presented with bleomycin-associated pulmonary toxicity.
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Introduction
Bleomycin, an antibiotic agent with antitumour activity, is an
important drug in the management of many oncological malig-
nancies such as lymphoma and germ cell tumours. These
tumours are potentially curable and mostly affect young people.
The potential side effects and long-term toxicities should be con-
sidered. The major limitation of bleomycin therapy is pulmonary
toxicity and may be life threatening in about 10% of cases.1–3
This article reports a case of an ovarian mixed germ cell tumour,
who received bleomycin-containing chemotherapy and pre-
sented with bleomycin-associated pulmonary toxicity.
Ethics
The Human Research Ethics Committee (HREC) of Stellenbosch
University approved the present report.
Case study
A 27-year-old woman, gravida 0, presented post-laparotomy for
a right ovarian mass when a right ovarectomy and omentum
biopsy was performed. Histology of the right ovary confirmed
a mixed germ cell tumour consisting of dysgerminoma (70%),
yolk sac tumour (25%) and immature teratoma (5%) that also
involved the omentum. Systemic evaluation for metastases
was negative and according to the International Federation of
Gynecology and Obstetrics classification (FIGO) was staged as
a FIGO stage IIIB nonseminomatous germ cell tumour and stan-
dard chemotherapy with the BEP regime (bleomycin 30 IU day 1,
8 and 15; etoposide 100 mg/m2 days 1 to 5, and cisplatin
20 mg/m2 days 1 to 5 every 3 weeks) was initiated. Pending
her biomarker response, tolerability and toxicity, four to six
cycles of BEP were planned.
Cycle 2 was delayed due to an episode of neutropenic sepsis;
this resolved and Cycle 2 was completed. Again she was read-
mitted with neutropenic sepsis and signs of an acute renal
injury syndrome (ARI). With a creatinine value of 284 µmol/l
(49–90 µmol/l) and a creatinine clearance of 30.5 ml/min (Cock-
croft–Gault formula), a nephrology consult and conservative
management the renal output improved and possible proximal
tubule damage was attributed to cisplatin administration and
sepsis. Nephrology advised against any chemotherapy adminis-
tration for at least a six-month period.
After extensive consultation with the patient and family she
opted for an alternative, less nephrotoxic regime, carboplatin
300 mg/m2 on day 1, etoposide 135 mg/m2 on days 1 to day 3
and bleomycin 30 IU on day 1 (CEB) with granulocyte colony-sti-
mulating factor (G-CSF) support from days 5 to 10, post-
chemotherapy to maintain dose intensity in a potentially
curable cancer. She completed three cycles of CEB. Bleomycin
was administered on D1, D8 and D15 of cycle 1 and 2 but
only on day 1 of cycles 3–5 due to the underlying concern
regarding potential toxicity. The cumulative bleomycin dose
was 270 mg, well within the maximum allowed lifetime
amount of 400–450 mg.
Initial preoperative biochemical markers included a raised alpha-
fetoprotein (AFP) 19 016 μg/l (0.0–7.0 μg/l), human chorionic
gonadotropin (HCG) 892 IU/l (< 5 IU/l) and lactate dehydrogen-
ase (LDH) 4 741 U/l (100–190 U/l). At the onset of chemotherapy,
the marker values decreased to AFP 733 μg/l, HCG 39 IU/l and
LDH 275 U/l. Her biochemical markers normalised at cycle 3
(Figure 1). At the completion of cycle 5 a lung-abdominopelvic
computer tomography scan (CT scan) revealed no signs of meta-
static disease in either the abdomen or chest but peripheral reti-
cular changes in the lung fields and areas of airspace
opacifications confirmed the radiological appearance of active
interstitial fibrosis of both lungs (Figure 2a).
However, four weeks post-completion of chemotherapy she
was admitted with signs and symptoms of severe anaemia –
haemoglobin 4 gm/dl (12.0–15.0 gm/dl) – and associated
increase in shortness of breath (SOB). Supportive care included
a red blood cell transfusion, oxygen and prednisone, but pro-
gressive worsening in SOB with oxygen dependency necessi-
tated intubation and a follow-up lung CT scan to exclude the
possibility of a pulmonary embolism. The fibrotic changes in
the lung had undergone progression and together with bilat-
eral ground-glass opacification were consistent with a non-
specific interstitial pneumonitis (NSIP) pattern of lung disease.
A significant pneumomediastinum and left pneumothorax
was observed and compared with the initial CT scan had
progressed (Figures 2b and 3). No pulmonary emboli were
demonstrated. A GeneXpert sputum test was negative for pul-
monary tuberculosis as was an immune-fluorescent assay for
Pneumocystis jirovecci.
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Discussion
Ovarian germ cell neoplasms arise in women between the ages
of 10 and 30 years, derived from primordial germ cells of the
ovary, and may be either benign or malignant but account for
only 5% of all malignant ovarian neoplasms. Ovarian mixed
germ cell tumours consist of two or more types of germ cell neo-
plasms and often secrete tumour markers, such as alpha-feto-
protein (AFP), human chorionic gonadotropin (HCG), or lactate
dehydrogenase (LDH).4
The staging procedure for women with ovarian germ cell
tumours is the same as for epithelial ovarian cancer. The majority
of women undergo surgical cytoreduction before the start of
chemotherapy and this is in direct contrast to testicular
cancer, where surgery is reserved for residual masses post-che-
motherapy. Post-surgery most women will receive adjuvant
platinum-based chemotherapy with curative intent. Cisplatin-
based chemotherapy for 3–6 cycles is considered the standard
of care. Long-term cure rates are > 90% for early-stage and up
to 80% for advanced disease.4–7
Drugs may produce a variety of respiratory tract disorders. Pul-
monary infiltrates with fibrosis may result from the use of cyto-
toxic drugs used in the treatment of cancer and the most
common cause of these reactions is bleomycin. The mechanism
for the development of bleomycin pulmonary-induced injury is
not clear but appears to involve the induction of free radicals
and cytokines that result in endothelial damage. Bleomycin
directly activates alveolar macrophages that subsequently
produce cytokines and free radicals resulting in fibroblast acti-
vation with accompanying deposits of collagen. Other com-
ponents might include a deficiency in the bleomycin
hydrolase enzyme and a possible genetic susceptibility.2,3
There is an increased risk of lung injury associated with the
administration of > 400 mg of bleomycin, although injury can
occur at doses as low as 50 mg. The risk appears higher in the
older patient (> 40 years) and in patients with renal insufficiency.
These patients should be spared exposure to bleomycin unless
equally effective alternative regimens are not available. Thoracic
irradiation and concurrent high-dose cisplatin administration
increase the risk of bleomycin lung toxicity and in animal
studies concomitant administration of granulocyte colony-sti-
mulating factor (G-CSF) was identified as a possible risk factor
for bleomycin-induced lung injury.1–3
Clinical manifestations occur between one and six months post-
bleomycin administration, but even occur during the
Figure 1: Biochemical marker response. AFP = alpha-fetoprotein; HCG = human chorionic gonadotropin; LDH = lactate dehydrogenase.
Figure 2: (a) Initial and (b) follow-up CT scan: upper lungs axial CT slices (lung windows): (a) There is intra- and inter-lobular septal thickening with
associated ground-glass opaciﬁcation and an incidental small-volume pneumomediastinum, the aetiology of which is not clear, possibly related to
an air leak from the adjacent lung pathology. The lung changes are consistent with an NSIP pattern of lung injury or an organising pneumonia. (b)
Interval progression is noted in terms of severity as well as area of the lung involved. There is now diffuse ground-glass opaciﬁcation of the lungs
as well as established ﬁbrosis with regions of honeycombing. The large ground-glass component suggests an active cellular component to the
disease and the radiological picture favours a mixed cellular ﬁbrotic NSIP pattern of lung injury. The pneumomediastinum progressed and there is a
left-sided pneumothorax.
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administration of bleomycin. Symptoms and signs include a
non-productive cough, dyspnoea, pleuritic or substernal chest
pain, fever, tachypnoea, lung restriction and hypoxemia. The
use of pulmonary function tests (PFTs), particularly the diffusing
capacity of the lung for carbon monoxide (DLCO) to screen for
evidence of pulmonary toxicity, has been controversial. The
assessment of PFTs, including spirometry and a DLCO, at base-
line and prior to each new treatment cycle is recommended
for most patients with germ cell tumours who receive a bleomy-
cin-containing regimen. It is recommended to discontinue bleo-
mycin therapy if an asymptomatic ≥ 25% decrease in the DLCO
is observed. Routine chest radiographs in asymptomatic people
are not recommended.2,3,8
Four types of lung toxicity are associated with the administration
of bleomycin: (1) subacute progressive pulmonary fibrosis, (2)
hypersensitivity pneumonitis, (3) organising pneumonia, and
(4) an acute chest pain syndrome that can occur during rapid
infusion. The classic chest radiological pattern of bleomycin-
induced fibrosis includes bibasilar sub-pleural opacities with
volume loss and blunting of the costophrenic angles; however,
fine nodular densities may be seen. Honeycombing may
develop as fibrosis progresses. Pneumomediastinum and pneu-
mothorax might be rare complications of bleomycin-related
lung fibrosis.2,3,9–11 The differential diagnosis includes infection,
venous thromboembolism and, depending on age, assessment
for cardiac failure or a myocardial infarction and pulmonary
hypertension, metastatic disease and radiation-induced lung
fibrosis should be undertaken. Management of suspected bleo-
mycin lung-induced toxicity includes discontinuation of bleomy-
cin therapy and for symptomatic patients a trial course of
prednisone is recommended for 4–6 weeks; if there is a response
to this, then the prednisone dose should gradually be
tapered.2,3,12,13
During the management of this case, we observed several treat-
ment-related complications and toxicities that required urgent
medical intervention: the patient experienced neutropenic
sepsis on two occasions that was treated and prevented in suc-
cessive cycles by the administration of prophylactic G-CSF. She
developed a severe acute renal injury syndrome (creatinine
clearance of 30 ml/min) secondary to sepsis and cisplatin admin-
istration and was managed with conservative treatment. A
nephrology consult suggested a six-month ban on further che-
motherapy administration but dealing with a curable disease
made for serious ethical consideration and discussion with
both the patient and her family. When she presented with
severe anaemia (Hb 4 gm/dl), the lung injury was diagnosed
on clinical symptoms that she experienced and the radiological
signs that confirmed the lung fibrosis (diffuse ground-glass opa-
cification of both lungs as well as established fibrosis with
regions of honeycombing). She also experienced the rare com-
plication of a pneumothorax and pneumomediastinum as a
result of the related lung fibrosis.
Eventually, our patient was admitted into the high care facility
and managed on a respirator, as she was unable to maintain
her oxygen saturation levels. The outcome was dismal when
she decompensated and developed an asystole.
Conclusion
Ovarian germ cell tumours generally have a good prognosis and
even in advanced disease almost 80% of patients will have long-
term survival. The chemotherapy regimens used to treat these
tumours are platinum based and BEP is the recommended stan-
dard of care. However, these drugs are not without short- and
long-term toxicities and, although rare, the consequences can
be fatal. Here we described a case that experienced fatal bleo-
mycin-induced pulmonary fibrosis. The practical approach to
prevent bleomycin-induced lung toxicity is to perform routine
PFTs in patients with germ cell tumours undergoing a bleomy-
cin-containing regime.
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